Implications of the Anavex Pipeline
This is by no means any sort of exhaustive discourse on the other molecules (beyond Anavex 2-73) in the company’s pipeline; merely a short presentation on my perceptions of such.
By now there is a rather extensive availability of papers and presentations on the science of Anavex 2-73. Needless to say, this molecule holds the strong promise of being able to effectively stop, or even reverse, the course of Alzheimer’s disease progression. It will be able to do this because it a) has virtually no side effects, and b) uniquely, unlike any other drug in any company’s pipeline, restores normalized neuron chemical functions, reverting neurons to normal pre-disease states, the so-called “homeostasis.”
How Anavex 2-73 does this has been previously explained. It should be known by new Anavex equity investors; as it is by Big Pharma executives and researchers. The cellular and chemical methods involved with Anavex 2-73 safety and efficacies are unique, and will prove, I believe, to be utterly revolutionary.
Now, after spending some time scrutinizing the available documentation on the other molecules in the Anavex pipeline, particularly Anavex 3-71, which appears to be everything and much more than A2-73, it appears to me that Anavex Life Sciences Corp. will be able, in time, to simply solve a massive number of modern health problems, not just Alzheimer’s.
In fact, most of the symptoms of these diseases occur because normal cell functions, whether in neurons, heart cells, or many others, come about because intracellular communications and organelle connections have been disrupted. Simply, Anavex molecules put cellular things back together again, allowing normal, non-disease functioning. Sounds too simple and too good to be true. But the mechanisms by which homeostasis is restored by each of the Anavex pipeline drug candidates have been rather precisely determined, or at least, observed, by substantiating testing in lab rats and mice.
Frankly, were I a corporate research director for a Big Pharma (I’m not; I’m a field biologist and former biology instructor) I’d do every thing I could to get access to all of the Anavex molecules, for development into remarkable new drugs, which have gigantic market sizes
The implications, then, of all of this? Be assured, any discussions between Anavex principals and those of other drug firms involve all of this. The game will not be played with only Anavex 2-73 in the lineup. Sitting on the Anavex bench, ready for substitution, is Anavex 3-71, which has even better preclinical stats than A2-73.
Anavex has a strong A2-73 first-team, about to start playing real games — which it will win hands down.
But on the Anavex bench is A3-71, getting ready to enter a starting lineup. Once in play (meaning, human trials results), it will score and win even better than A2-73.
It’s easy to disregard the many other players Anavex has still suiting up back in the lab locker rooms; chemicals that will play games against many diseases beyond Alzheimer’s and Parkinson’s, and win handily, I believe.
So, any buy-out or collaboration discussions between Anavex and any Big Pharma must take into account all of what Anavex possesses, the entire team, revolutionary new drugs that will have massive target clienteles and be uniquely successful. It’s not just Anavex 2-73 and Alzheimer’s, by any means.
And the Anavex principals, more than any, know all of this. They will be driving some very hard deals, should any be needed or transpire.
The presumption that AVXL is a $4 to $5 stock, based on the available science, is ludicrous.
AI
